Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNSR NASDAQ:NEPH NASDAQ:PDEX NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNSRLENSAR$13.24+0.7%$13.19$3.50▼$17.31$155.39M0.593,281 shs43,453 shsNEPHNephros$3.59+3.9%$3.37$1.36▼$5.00$37.99M1.0918,506 shs12,680 shsPDEXPro-Dex$47.05-1.0%$43.50$17.81▼$70.26$154.24M0.1937,801 shs34,341 shsRCELAvita Medical$5.38-0.9%$5.82$4.71▼$14.16$142.06M1.52191,444 shs1,650 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNSRLENSAR+0.38%+0.61%+7.32%-5.18%+148.40%NEPHNephros+3.77%-4.53%-5.29%+82.75%+65.74%PDEXPro-Dex-0.55%-1.03%+10.88%-22.29%+137.54%RCELAvita Medical+1.88%-8.59%+4.22%-41.04%-46.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLNSRLENSAR1.2004 of 5 stars2.02.00.00.02.72.50.0NEPHNephros2.8037 of 5 stars3.55.00.00.02.70.80.0PDEXPro-Dex2.1944 of 5 stars2.52.00.00.02.21.71.9RCELAvita Medical1.3795 of 5 stars3.40.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNSRLENSAR 2.00Hold$15.0013.34% UpsideNEPHNephros 3.00Buy$5.0039.47% UpsidePDEXPro-Dex 3.00Buy$56.0019.03% UpsideRCELAvita Medical 2.75Moderate Buy$16.50206.52% UpsideCurrent Analyst Ratings BreakdownLatest NEPH, RCEL, LNSR, and PDEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNSRLENSAR$53.49M2.92N/AN/A$0.42 per share31.51NEPHNephros$14.16M2.68$0.02 per share172.41$0.81 per share4.43PDEXPro-Dex$53.84M2.85$0.95 per share49.64$9.03 per share5.21RCELAvita Medical$64.25M2.21N/AN/A$0.17 per share31.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNSRLENSAR-$31.40M-$4.85N/A∞N/A-99.17%-737.30%-81.69%8/14/2025 (Estimated)NEPHNephros$70K$0.0751.21∞N/A5.16%9.43%7.20%8/6/2025 (Estimated)PDEXPro-Dex$2.13M$2.8016.9022.84N/A14.61%29.08%16.19%9/4/2025 (Estimated)RCELAvita Medical-$61.85M-$2.19N/AN/AN/A-79.61%-632.62%-71.72%8/6/2025 (Estimated)Latest NEPH, RCEL, LNSR, and PDEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RCELAvita Medical-$0.26N/AN/AN/AN/AN/A5/15/2025Q1 2025NEPHNephros-$0.0050$0.0526+$0.0576$0.05$3.67 million$4.88 million5/8/2025Q1 2025LNSRLENSAR-$0.1550-$2.32-$2.1650-$2.32$13.40 million$11.53 million5/8/2025Q1 2025RCELAvita Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLNSRLENSARN/AN/AN/AN/AN/ANEPHNephrosN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNSRLENSARN/A1.811.25NEPHNephrosN/A5.924.64PDEXPro-Dex0.282.731.45RCELAvita Medical9.392.091.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNSRLENSAR40.15%NEPHNephros41.10%PDEXPro-Dex15.28%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipLNSRLENSAR38.52%NEPHNephros6.70%PDEXPro-Dex47.50%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNSRLENSAR11011.79 million7.25 millionOptionableNEPHNephros3010.60 million9.89 millionNot OptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableRCELAvita Medical13026.43 million25.70 millionOptionableNEPH, RCEL, LNSR, and PDEX HeadlinesRecent News About These CompaniesAvita Medical Ltd (RCEL) Stock Forums - Investing.comJune 30, 2025 | investing.comAVITA Medical, Inc. (RCEL) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comAnalysts Expect Breakeven For AVITA Medical, Inc. (NASDAQ:RCEL) Before LongJune 21, 2025 | finance.yahoo.comAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™June 5, 2025 | finance.yahoo.comAVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough AwardsJune 3, 2025 | globenewswire.comAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live TodayMay 13, 2025 | finance.yahoo.comAVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet ChallengesMay 12, 2025 | seekingalpha.comAnalysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest ReportMay 11, 2025 | finance.yahoo.comAVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAVITA Medical Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAVITA Medical to Announce First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comAVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025April 9, 2025 | globenewswire.com6 Analysts Assess AVITA Medical: What You Need To KnowApril 6, 2025 | nasdaq.comAvita Medical announces U.S. commercial launch of CohealyxApril 4, 2025 | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3, 2025 | globenewswire.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comAvita Medical amends PermeaDerm distribution agreement with Stedical ScientificMarch 17, 2025 | markets.businessinsider.comAvita Medical Boosts Production with New AgreementMarch 17, 2025 | tipranks.comAVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical ScientificMarch 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseUPS Is Outpacing the Market: A Green Light for Investors?By Jeffrey Neal Johnson | June 27, 2025View UPS Is Outpacing the Market: A Green Light for Investors?NEPH, RCEL, LNSR, and PDEX Company DescriptionsLENSAR NASDAQ:LNSR$13.24 +0.10 (+0.72%) As of 09:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.Nephros NASDAQ:NEPH$3.58 +0.14 (+3.91%) As of 09:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Pro-Dex NASDAQ:PDEX$47.04 -0.49 (-1.02%) As of 09:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.Avita Medical NASDAQ:RCEL$5.38 -0.05 (-0.87%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
